Core Viewpoint - Rigel Pharmaceuticals is expected to report strong earnings for Q4 and full-year 2024, with significant growth in product sales and positive guidance for 2025 [1][6][19]. Financial Performance - The Zacks Consensus Estimate for Q4 2024 sales is $57.57 million, with earnings per share (EPS) expected at 42 cents [1]. - The EPS estimate for 2024 has increased from 17 cents to 22 cents over the past 60 days, while the 2025 EPS estimate has risen from 92 cents to $1.05 [1][2]. - Rigel's total revenues for Q4 2024 are projected to be $57.6 million, up from $35.8 million in the same period last year [6]. Product Sales - Tavalisse is expected to generate quarterly net product sales of $31.0 million, contributing significantly to Rigel's revenue growth [6]. - The company anticipates net product sales of $7.4 million from Rezlidhia and $8.1 million from Gavreto [8][9]. - Total revenues for 2024 are expected to reach $179.3 million, including net product sales of $144.9 million and contract revenues of $34.4 million [11]. Market Position and Valuation - Rigel's shares have increased by 50.6% over the past year, contrasting with a 13.4% decline in the industry [12]. - The current price/sales ratio for Rigel is 1.86x forward sales, lower than its historical mean of 2.37x but higher than the drug industry average of 1.64x [13]. Growth Outlook - Rigel expects total revenues of approximately $200-$210 million in 2025, with product sales projected between $185-$192 million [16]. - The company anticipates achieving positive net income in 2025 while continuing to fund clinical development programs [16]. - Rigel's pipeline includes promising candidates, with R289 receiving Orphan Drug and Fast Track designations for the treatment of myelodysplastic syndromes [17][18].

Core Viewpoint - Rigel Pharmaceuticals, Inc. will report its fourth quarter and full year 2024 financial results on March 4, 2025, followed by a live conference call to discuss the results and business updates [1]. Company Information - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel therapies for patients with hematologic disorders and cancer, founded in 1996 and based in South San Francisco, California [3]. - The company is listed on Nasdaq under the ticker symbol RIGL [1]. Conference Call Details - The live conference call can be accessed by dialing 877-407-3088 for domestic participants and 201-389-0927 for international participants [2]. - The conference call will also be webcast live and available for replay for 90 days after the call on the company's website [2].

Core Viewpoint - Rigel Pharmaceuticals, Inc. (RIGL) has demonstrated significant stock performance, with a 41.4% increase over the past year, contrasting with a 13.4% decline in the biotechnology industry, driven by strong sales of its leading drug Tavalisse and progress in its drug pipeline [1][2]. Group 1: Product Performance - Tavalisse, Rigel's first approved product, generated $104.8 million in net product sales in 2024 and is the only approved oral SYK inhibitor for chronic immune thrombocytopenia (ITP) [3][4]. - Rigel's second FDA-approved product, Rezlidhia, is aimed at treating relapsed or refractory acute myeloid leukemia (AML) and has been licensed from Forma with exclusive worldwide rights [5]. - The company added Gavreto to its portfolio in 2024, which became commercially available in June and contributed positively to the company's revenue [8]. Group 2: Pipeline Development - Rigel is advancing its pipeline, with R289 receiving Orphan Drug designation for myelodysplastic syndromes (MDS) and undergoing a phase Ib study [10]. - The FDA has granted Fast Track designation for R289, and Rigel is also conducting a phase Ib/II trial combining Rezlidhia with other therapies for mIDH1 AML [11]. Group 3: Financial Outlook - Rigel anticipates total revenues of approximately $200-$210 million in 2025, with product sales expected to be around $185-$192 million, and projects positive net income for the year [12]. - The Zacks Consensus Estimate for 2024 earnings per share (EPS) has increased to 22 cents from 17 cents, while the estimate for 2025 has risen to $1.05 from $0.92 [14]. Group 4: Valuation and Market Position - RIGL shares currently trade at a price/sales ratio of 1.74x forward sales, lower than its historical mean of 2.38x but higher than the industry average of 1.64x [13]. - The company is viewed positively due to its strong performance in 2024 and optimistic guidance for 2025, suggesting potential for further growth [16][17].

Shares of Rigel Pharmaceuticals (RIGL) have gained 24.6% over the past four weeks to close the last trading session at $21.65, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $30.50 indicates a potential upside of 40.9%.The average comprises six short-term price targets ranging from a low of $14 to a high of $57, with a standard deviation of $17.85. While the lowest estimate ind ...

First patient enrolled in NIH/NHLBI-sponsored Phase 1 Study of fostamatinib, Rigel's oral SYK inhibitorSOUTH SAN FRANCISCO, Calif., Jan. 22, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the first patient has been enrolled in a Phase 1 study evaluating the safety and tolerability of escalating doses of fostamatinib, the company's oral spleen tyrosine kinase (SYK) inhibitor, in patients with sickle cell disease (SCD). The study is being sponsored by the National Heart, Lung, ...

Rigel Pharmaceuticals (RIGL) closed the last trading session at $17.35, gaining 0.8% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $30.50 indicates a 75.8% upside potential.The mean estimate comprises six short-term price targets with a standard deviation of $17.85. While the lowest estimate of $14 indicates a 19.3% decline from the current price level, the most optimistic analys ...

Rigel Pharmaceuticals (RIGL) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.Individual inve ...

Core Viewpoint - Rigel Pharmaceuticals reported a transformational year in 2024, achieving record sales and reaching financial breakeven, while advancing its development pipeline and planning for growth in 2025 [2][5][13]. Preliminary Financial Results - Preliminary total revenue for Q4 2024 is approximately $57.6 million, a significant increase from $35.8 million in Q4 2023 [5][6]. - Net product sales for Q4 2024 include TAVALISSE at $31.0 million, REZLIDHIA at $7.4 million, and GAVRETO at $8.1 million [5][6]. - For the full year 2024, Rigel expects total revenue of $179.3 million, up from $116.9 million in 2023, with net product sales of $144.9 million [5][6]. Commercial Update - TAVALISSE surpassed $100 million in net product sales in 2024, reporting $104.8 million [12]. - Rigel entered an exclusive license agreement with Dr. Reddy's for REZLIDHIA, which includes an upfront payment of $4.0 million and potential future milestone payments of up to $36.0 million [12]. Clinical and Development Update - R289 received Orphan Drug designation from the FDA for treating MDS and is currently in a Phase 1b clinical study [5][12]. - Initial data from the R289 study presented at the ASH Annual Meeting showed promising safety and efficacy results [12]. - Rigel plans to initiate a Phase 2 clinical study in recurrent glioma in 2025 [13]. 2025 Outlook - Rigel anticipates total revenue for 2025 to be approximately $200 to $210 million, with expectations of positive net income [13]. - The company aims to continue advancing its commercial portfolio and clinical development programs [13].

FDA Designations and Development Progress - The US FDA granted Orphan Drug designation to R289 for the treatment of myelodysplastic syndromes (MDS), highlighting the unmet medical need for patients with this rare disorder [1][2] - R289 also received Fast Track designation for the treatment of previously-treated transfusion-dependent lower-risk MDS patients [3] - The ongoing Phase 1b study of R289 is evaluating its safety, tolerability, pharmacokinetics, and preliminary activity in patients with lower-risk MDS who are relapsed or refractory to prior therapies [1] R289 Mechanism and Potential - R289 is a prodrug of R835, a dual inhibitor of IRAK1 and IRAK4, which blocks inflammatory cytokine production in response to TLR and IL-1R signaling [4] - Chronic stimulation of TLR and IL-1R pathways is thought to cause the pro-inflammatory environment in the bone marrow responsible for persistent cytopenias in lower-risk MDS patients [4] - Initial data from the Phase 1b study of R289 in lower-risk MDS patients is encouraging, supporting its potential as a new treatment option [2] Company Overview - Rigel Pharmaceuticals is a biotechnology company focused on discovering, developing, and providing novel therapies for hematologic disorders and cancer [5] - Founded in 1996, Rigel is based in South San Francisco, California, and is listed on the Nasdaq under the ticker RIGL [5]

SOUTH SAN FRANCISCO, Calif., Jan. 8, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced that Raul Rodriguez, the company's president and CEO, will present a company overview at the 43rd Annual J.P. Morgan Healthcare Conference on Thursday, January 16, 2025 at 8:15 a.m. PT (11:15 a.m. ET) in San Francisco, CA. To access the live webcast or archived recording, visit the Investor Relations sectio ...